You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management

Food and Drug Administration

5630 Fishers Lane, Rm 1061

Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2020-D-1106.